Pub. Date : 2010 Jan
PMID : 19843070
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
1 | Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells. | Imatinib Mesylate | mitogen-activated protein kinase 3 | Homo sapiens |
2 | In both cell lines, imatinib effectively reduced the phosphorylation of all the above, except ERK1/2, whose phosphorylation was, interestingly, only inhibited in the wild-type cells. | Imatinib Mesylate | mitogen-activated protein kinase 3 | Homo sapiens |
3 | However, using an ERK1/2 inhibitor, U0126, we found that we could reduce phospho-ERK1/2 levels in K562/R cells and restore their sensitivity to imatinib. | Imatinib Mesylate | mitogen-activated protein kinase 3 | Homo sapiens |
4 | However, using an ERK1/2 inhibitor, U0126, we found that we could reduce phospho-ERK1/2 levels in K562/R cells and restore their sensitivity to imatinib. | Imatinib Mesylate | mitogen-activated protein kinase 3 | Homo sapiens |
5 | Taken together, we conclude that the BCR-ABL-independent activation of ERK1/2 contributes to imatinib resistance in K562/R cells, and that ERK1/2 could be a target for the treatment of CML patients whose imatinib resistance is due to this mechanism. | Imatinib Mesylate | mitogen-activated protein kinase 3 | Homo sapiens |
6 | Taken together, we conclude that the BCR-ABL-independent activation of ERK1/2 contributes to imatinib resistance in K562/R cells, and that ERK1/2 could be a target for the treatment of CML patients whose imatinib resistance is due to this mechanism. | Imatinib Mesylate | mitogen-activated protein kinase 3 | Homo sapiens |
7 | Taken together, we conclude that the BCR-ABL-independent activation of ERK1/2 contributes to imatinib resistance in K562/R cells, and that ERK1/2 could be a target for the treatment of CML patients whose imatinib resistance is due to this mechanism. | Imatinib Mesylate | mitogen-activated protein kinase 3 | Homo sapiens |